Tomasz Jurga, PharmD, BCPS, BCACP

home / authors / tomasz-jurga-pharmd-bcps-bcacp

Articles

COVID-19: Caring for Patients With Cardiovascular Disease in the Outpatient Setting

COVID-19: Caring for Patients With Cardiovascular Disease in the Outpatient Setting

Tomasz Jurga, PharmD, BCPS, BCACP
May 1st 2020

Engaging in discussions with patients at high risk of complications from COVID-19 without seeming patronizing is an important skill that many pharmacists should practice.

Read More

Should Patients Continue Using Cardiovascular Disease Drugs During COVID-19 Pandemic?

Should Patients Continue Using Cardiovascular Disease Drugs During COVID-19 Pandemic?

Tomasz Jurga, PharmD, BCPS, BCACP
March 18th 2020

Recently, many providers have become worried about the potential of certain medications to worsen transmission and outcomes in the setting of the global COVID-19 pandemic.

Read More

Latest Updated Articles

AI patient pharmacist provider interactions ASHP summer
Published: June 11th 2024 | Updated: July 27th 2024
Balancing Trust and Technology: The Role of AI in Patient-Pharmacist Interactions
AI pharmacy futures AI disparities skin
Published: June 11th 2024 | Updated: July 27th 2024
Addressing Disparities in AI-Driven Diagnostics: Ethical and Practical Implications
Vice President Kamala Harris -- Image credit: Erin Schaff/Pool/AFP | GETTY | People.com
Published: July 23rd 2024 | Updated: July 27th 2024
VP Kamala Harris’s Policies and Stances on Health Care, Reproductive Rights Take Center Stage
3d illustration of Abstract medical background with Diseased liver - Image credit: Rasi | stock.adobe.com
Published: October 18th 2023 | Updated: July 27th 2024
Pharmacists Can Optimize Treatment for Patients with NASH, Decreasing Economic Burden
Small vial of influenza vaccine.
Published: July 23rd 2024 | Updated: July 27th 2024
Trivalent Influenza Vaccines Are Readied for Fall
Eye Care Pharmacy | Image Credit: I Viewfinder - stock.adobe.com
Published: July 15th 2024 | Updated: July 27th 2024
Biosimilar Ranibizumab Could be More Cost-Effective Than Aflibercept for nAMD